Science & Technology
Designing safe, potent, and cost-effective small peptide erythropoietin analogs
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43HL167440-01
Award Ceiling
$250K
Award Floor
$250K
Close Date
Sep 9, 2024
Total Funding
$250K
Expected Awards
1
Posted Date
Sep 10, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43HL167440-01
Description
SBIR Phase Phase I award: "Designing safe, potent, and cost-effective small peptide erythropoietin analogs" awarded to Covenant Therapeutics LLC in CHARLOTTESVILLE, Virginia. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $249,965. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.